-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
Educational Session to Provide Update on Recent Progress in Treatment of ‘Extensive-Stage’ SCLC
Drs. Hidehito Horinouchi and Stephen Liu will chair the session, which will explore multiple advances driving survival gains, including antibody-drug conjugates, bispecific T-cell engagers, and targeted therapies.
-
New Strategic Plan to be Unveiled at IASLC Business Meeting
Members are invited to join the meeting and learn about the new plan, which will guide the association for the next 5 years.
-
Opening Plenary Session Examines Treatment Inequities, Humanitarian Toll of Lung Cancer
In addition to thought-provoking keynotes from Her Royal Highness Princess Dina Mired and Dr. Gary Rodin, the official kickoff of #WCLC23 included a lively celebration of the meeting’s host city.
-
Novel Immunochemotherapy / Anti-Angiogenesis Combo Shows Best Survival to Date for ES-SCLC
Investigator Dr. Ying Cheng says study results support the use of immunochemotherapy plus anti-angiogenesis as a new treatment option in a difficult-to-treat patient population.
-
Final Poster Networking Reception Tonight
Make time to visit the Exhibit Hall this evening to talk with poster presenters about their research.
-
Presidential Symposium to Highlight Late-Breaking, Practice-Changing Research
The symposium also marks a change in IASLC leadership as Dr. Heather Wakelee will deliver the final Presidential Address of her term.
-
Plenary 4 Offers Early Look at 9th Edition of TNM Staging Classification for Thoracic Cancers
IASLC Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura joins Drs. Valerie Rusch and Enrico Ruffini to review updates in lung cancer, mesothelioma, and thymic cancer.
-
Annual Award Recognizes Importance of Multidisciplinary Teams
The IASLC Cancer Care Team award highlights the teamwork required to provide the best possible patient care.
-
IASLC Journals See Positive Changes in Past Year
Since WCLC 2022, JTO, led by Dr. Alex A. Adjei, has continued to increase its impact factor, and JTO CRR has welcomed a new Editor-in-Chief, Dr. Emily Stone.
-
Her Royal Highness Princess Dina Mired of Jordan Sees Challenges and Progress in Global Cancer Care
In an exclusive interview, Princess Dina talks with ILCN about her passion for improving equitable access to cancer care, tobacco control, prevention, and more.